News|Articles|September 1, 2003

Aloxi (Palonosetron)

5-HT3 receptor antagonist indicated to prevent delayed CINV


Related to this article

Medicare Part D redesign reshapes market
Part D enrollment has shifted: standalone plan offerings are down 22%, while special needs plans grew 21%, reshaping competition among fewer, larger sponsors nationally, finds an analysis by IPD Analytics.